Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Fruquintinib |
Trade Name | Fruzaqla |
Synonyms | HMPL-013 |
Drug Descriptions |
Fruzaqla (fruquintinib) binds and inhibits VEGFR1/2/3, potentially resulting in reduced cell proliferation and decreased tumor growth (PMID: 25482937, PMID: 31790382). Fruzaqla (fruquintinib) is FDA approved for use in patients with metastatic colorectal cancer who have received prior therapy (FDA.gov). |
DrugClasses | VEGFR Inhibitor (Pan) 36 |
CAS Registry Number | 1194506-26-7 |
NCIT ID | C102852 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ensartinib + Fruquintinib | Ensartinib Fruquintinib | 0 | 0 |
Fruquintinib | Fruquintinib | 0 | 2 |
Fruquintinib + Paclitaxel | Fruquintinib Paclitaxel | 0 | 0 |
Fruquintinib + Sintilimab | Fruquintinib Sintilimab | 0 | 0 |
Fruquintinib + Tislelizumab | Fruquintinib Tislelizumab | 0 | 1 |